|  |  |  |  |
| --- | --- | --- | --- |
| **SITE AND PARTIPANT INFORMATION** | | | |
| Site Name: |  | Query Date: | DD/MM/YY. |
| Staff Name: |  | Staff Email Address: |  |
| Participant ID: |  | Participant Age: |  |

|  |
| --- |
| **REASON FOR QUERY** |
| Request for consultation on clinical/laboratory evaluations related to eligibility determination |
| Request for consultation on clinical/laboratory evaluations related to study product management  Should study product be continued?  Should study product be temporarily held?  Should study product be permanently discontinued?  Should study product be resumed? |
| Request for consultation on AE management  Yes. Complete Section A and B, as appropriate  No. Skip to Narrative Summary |
| Other. Please Describe:  Click or tap here to enter text. |

|  |  |
| --- | --- |
| **SECTION A: ADVERSE EVENT (AE) INFORMATION** | |
| Primary AE of Concern: |  |
| Onset Date: | DD/MM/YY. |
| Severity Grade at Onset: | Grade 1 Mild  Grade 2 Moderate  Grade 3 Severe  Grade 4 Potentially Life-Threatening  Grade 5 Death |
| Relatedness to Study Product:  *(Record explanation in the Narrative Summary section*) | Related  Not Related |
| Relatedness to Study Procedure:  *(Record etiology or explanation in the Narrative Summary section)* | Related  Not Related |
| Current Study Product Administration: | Not Applicable  Continuing  Temporarily Held, as of DD/MM/YY.  Permanently Discontinued, as of DD/MM/YY. |
| Dose last administered to participant: | ☐ 1 insert 🡪 Date administered: DD/MM/YY.  ☐ 2 inserts 🡪 Date administered: DD/MM/YY.  ☐ N/A, prior to any study product use |
| Has this AE been reported on an AE Log CRF? | Yes  No |
| Has this AE been reported as an SAE/EAE? | Yes  No |
| Has this AE been evaluated more than once? | Yes. Complete Section B  No. Skip to Narrative Summary |

|  |  |
| --- | --- |
| **SECTION B: ADVERSE EVENT (AE) RE-ASSESSMENT INFORMATION** | |
| Date of Most Recent Evaluation: | DD/MM/YY. |
| Status of AE at Most Recent Evaluation: | Continuing, stabilized (severity grade unchanged)  Continuing, improving → severity grade decreased to: Enter Grade.  Continuing, worsening → severity grade increased to: Enter Grade.  Resolved |

|  |
| --- |
| **NARRATIVE SUMMARY** |
| *In the space provided below, please note as much detail as possible regarding the participant’s condition. Provide the participant’s gender, genital anatomy, describe the sequence of the signs and/or symptoms, and any additional relevant past medical history, diagnosis, intervention and/or treatment, relevant lab tests and results and current status of participant.* |
| Click or tap here to enter text. |
| *Proposed course of action:* |
| Click or tap here to enter text. |

**END OF FORM FOR SITE STAFF.**

Email completed form to the MTN-039 Protocol Safety Physicians [mtn039safetymd@mtnstopshiv.org](mailto:mtn039safetymd@mtnstopshiv.org). If an email response is not received from the PSRT within 3 business days, re-contact the Protocol Safety Physicians, copying the MTN-039 Management Team ([mtn039mgmt@mtnstopshiv.org](mailto:mtn039mgmt@mtnstopshiv.org)) assistance.

|  |  |  |  |
| --- | --- | --- | --- |
| **PSRT USE ONLY** | | | |
| PSRT Responding Member Name: | |  |
| PSRT Response Date: | |  |
| PSRT Comments: | | | |
| Click or tap here to enter text. | | | |
| Query Outcome: | Not Applicable  Approved  Not Approved | | |